NCT07197255Recruiting
Transcriptomic Profiling of Cumulus Cells From CAPA-IVM
Transcriptomic Profiling of Cumulus Cells From CAPA-IVM Cycles in Women With PCOS: A Prospective Pilot Study
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10 (estimated)
- First submitted
- 2 Sept 2025
- Start date
- 16 Oct 2025
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- Mỹ Đức Hospital
- NCT number
- NCT07197255
What you commit to
- Study type: Observational
- Planned participants: 10
- From 16 Oct 2025 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Retrieved sperm from surgical procedures
- Previous IVF cycle with total immature oocytes
Who the study is looking for
- Women 18-38 years
- BMI =\< 32kg/m2
- Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and/or biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound.
- Indicated for CAPA-IVM treatment.
- Serum AMH ≥ 4 ng/mL (28.57 pmol/L).
- Antral follicle count (AFC) ≥ 24 follicles in both ovaries at the time of CAPA-IVM indication.
- Signed informed consent to participate in the study.
Age in the registry: 18 years to 38 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| My Duc Hospital Coordinator of this site? Confirm its status | Ho Chi Minh City | Vietnam | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.